UTSA researchers and oncologists develop protein cancer atlas to accelerate personalized medicine for leukemia patients
To improve the survival rate of acute myelogenous leukemia patients, researchers at UTSA and the University of Texas MD Anderson Cancer Center created an online atlas to identify and classify protein signatures present at AML diagnosis.The new protein classifications will help researchers and clinicians recommend better treatment and personalized medicine for patients suffering from this aggressive cancer, which occurs in the blood and bone marrow, according to a University of Texas at San Antonio article. The breakthrough research is published in the latest April issue of Nature Biomedical Engineering.
Researcher Amina Qutub, an associate professor in the UTSA Department of Biomedical Engineering (who joined UTSA in 2018 from Rice University), and oncologist Steven M. Kornblau, a professor and practicing clinician in the Department of Leukemia at UT MD Anderson Cancer Center, examined the genetic, epigenetic and environmental diversity that occurs in cancerous cells due to AML. Qutub is a BMES member.
Analyzing proteomic screens of 205 patient biopsies obtained at MD Anderson Cancer Center, first author Chenyue Wendy Hu (then a graduate student at the Qutub Lab, now at Uber Technologies), Kornblau and Qutub developed a new computational method called MetaGalaxy to categorize the protein signatures into 154 different patterns based on their cellular functions and pathways, according to the article. Hu is a BMES member.
Read more HERE.